Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
-
NEW YORK, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
-
- Dr. Larrieux brings significant experience managing analytical development quality control of immunotherapies to treat cancer and small molecule therapies at pharmaceutical and biotechnology...
-
- Actimab-A has received Orphan Drug Designation in the U.S. - Orphan Designation in the EU can result in regulatory assistance, reduced fees and 10 years of market exclusivity ...
-
Patient focused webinar titled “Stem Cell Transplants for Acute Myeloid Leukemia: What you Need to Know” Webinar to be led by transplant expert, Dr. Patrick Stiff, Director of the Cardinal...
-
Analysis of 2 Actimab-A Phase 1 clinical trials show that 42% of patients with low peripheral blast (PB) burden responded to Actimab-A while no patients with high PB burden responded to Actimab-AKey...
-
NEW YORK, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
-
NEW YORK, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...
-
NEW YORK, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload...
-
Allowed patent application claims method for purifying actinium-225 NEW YORK, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a...